February 16, 2017
2 min read
Save

OCT angiography may be used to identify biomarkers of neovascular activity

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

MIAMI — Several biomarkers of neovascularization in age-related macular degeneration, such as secondary small vessel branching and greater fractal dimension, can be identified in patients by using OCT angiography.

Perspective from Nadia K. Waheed, MD, MPH

“Immature [neovascularization] may begin as a tangle of vessels and matures as a radiating lesion to core feeder vessels. ... Once they become mature we want to look at whether they’re quiescent or active. We have been able to identify these features indicating activity, whether they’re qualitative features or quantitative features, and the area and density may be biomarkers once you look at these lesions long term,” David Sarraf, MD, said at Angiogenesis, Exudation, and Degeneration 2017.

Using OCT angiography, ophthalmologists can identify biomarkers of activity. Sarraf said greater fractal dimension, peripheral arcades with anastomoses and secondary small vessel branching are all biomarkers of activity. However, absent peripheral arcades, lower fractal dimension, large dilated straight vessels and absence of secondary branching are biomarkers of inactivity, he said. – by Robert Linnehan

Reference:

Sarraf D. Biomarkers of neovascular activity using OCT angiography. Presented at: Angiogenesis, Exudation, and Degeneration 2017; Feb. 11, 2017; Miami.

Disclosure: Sarraf reports he is an advisory board or panel member for Optovue and Genentech; is a consultant for Bayer, Genentech and Optovue; receives grants/research support from Allergan, Heidelberg Engineering, Genentech, Regeneron and Optovue; is a member of the speakers bureau for Optovue and Novartis; and is a stock/shareholder of Optovue.